Two industry watchdogs have expressed apprehension regarding Google’s shift away from third-party cookies in Chrome towards a Privacy Sandbox initiative that relies on alternative ad-targeting methods. Both the IAB Tech Lab and the U.K.’s Competition and Markets Authority (CMA) have issued separate reports, raising concerns about the potential disadvantages for other players in the digital advertising ecosystem. They foresee fresh challenges emerging in areas such as ad fraud and brand safety. The IAB Tech Lab, which has made its findings available for public comment, asserted that the industry is not adequately prepared for this change. It argued that the adjustments to Chrome do not yet provide a “viable business foundation.” On the regulatory front, the CMA emphasized that Google should not proceed with third-party cookie deprecation until concerns about anticompetitive issues related to Privacy Sandbox are addressed. Despite Google delaying the demise of cookies multiple times since announcing its intention in 2020, industry watchdogs are now expressing concerns about the viability of transitioning to Privacy Sandbox in its current state. The initial phase of Google’s plan to deprecate cookies is now underway, with cookies gradually fading away for a small percentage of Chrome users since January. The broader deprecation is planned for the second half of 2024. Privacy Sandbox is centered around two alternative ad-targeting solutions: a Topics API based on user interests and a Protected Audience API, formerly known as FLEDGE. The IAB Tech Lab, a nonprofit consortium focusing on developing best practices for digital advertising, outlined key issues with Privacy Sandbox. It highlighted potential disruptions to the programmatic ecosystem caused by the implementation of an ad exchange and ad server in Chrome, as well as the loss of crucial data points for ensuring brand safety. The IAB Tech Lab anticipates that ad-tech firms on the supply and demand side may face significant costs in adapting their systems to these changes, while brands, agencies, and publishers may encounter operational, financial, and legal challenges. The analysis by the IAB Tech Lab involved consulting with 65 companies across various practices over six months and mainly focused on the implications of the Protected Audience APIs, with some discussion on other topics like the Topics API. Anthony Katsur, CEO of IAB Tech Lab, emphasized that embracing Google’s Privacy Sandbox represents a seismic shift in the advertising landscape, and their findings highlight that the industry is not yet ready, identifying multiple challenges to implementation. The CMA, acting as an antitrust regulator, shares concerns about Privacy Sandbox potentially giving Google an advantage and creating obstacles for smaller players in digital advertising. The reliance on first-party data, the Topics API taxonomy ownership, and potential industry-run governance were all raised as issues by the CMA. Google and the CMA are currently in a standstill period as they work on the specifics of moving forward with Privacy Sandbox, with the CMA planning to publish its next report update on the matter in April.

1. In 1974, Ramesh Juneja held the position of a medical representative at Kee Pharma, a pharmaceutical company. While on a field visit, he was deeply moved witnessing someone resorting to selling jewelry to pay for medicines. This experience fueled his desire to make medicine more affordable. 2. After dedicating eight years to another pharmaceutical company, Lupin, Ramesh contemplated a change. He ventured into establishing an antibiotics company, Bestochem, which unfortunately faced failure by 1994. Undeterred, Ramesh, along with his brother, started a pharmaceutical company with an initial investment of Rs 50 lakh in their hometown, Meerut, UP, giving birth to Mankind pharma Ltd in 1995. 3. The concept was straightforward: offer cost-effective, innovation-driven, high-quality pharmaceutical products to enhance patients’ lives. The company’s tagline was “Serving Life.” Ramesh initially focused on selling affordable painkillers and antibiotics but was aware of the challenge. 4. To enhance brand recognition, he began labeling medicines under the name “Mankind Pharma,” concentrating heavily on smaller towns and rural areas. Within the first year, Mankind pharma Ltd achieved a revenue of 3.79 crore. 5. The growth continued with just 25 sales executives, making a strong entry into the 2000s. Their blood pressure tablets, Amlokind and Glimestar, gained popularity, offering a cost advantage of nearly 50% compared to competitors like Cipla and Sun Pharma. In 2001, Ramesh inaugurated the first manufacturing plant in Paonta Sahib, Himachal Pradesh. 6. By 2005, Mankind Pharma joined the 500 crore turnover club, showcasing that a pharmaceutical company could achieve substantial sales growth within India. Encouraged by the success, the private equity firm Chrys Capital invested approximately 100 crore in Mankind pharma Ltd. However, Ramesh identified a crucial aspect of the business. 7. Ramesh recognized the need to sell medicines that didn’t require a doctor’s prescription. In 2007, he embraced the “Over the Counter (OTC)” approach, marking a transformative moment in Mankind’s history. 8. Star products like Manforce condoms and Prega News (Pregnancy Kits) were introduced, targeting the growing GenZ population with an extensive marketing budget of 50 crore. By 2010, Mankind Pharma joined the 1000 crore turnover club. 9. Mankind Pharma expanded its portfolio with antacids (Gas O fast) and nutraceuticals (Nurokind LC), and Manforce condoms evolved into a 100 crore brand. In 2015, the company joined the 5000 crore turnover club. 10. On April 25, 2023, Mankind Pharma went public with an IPO, raising 4326 crore. It achieved revenues of 7782 crore, becoming India’s 4th largest pharmaceutical company by domestic sales and the 2nd largest prescription drug maker. It transformed into an 80,000 crore company. Today, Mankind Pharma boasts a workforce of over 22,000 employees and 9,000 sales agents. Despite the company’s 22,000 crore valuation, Mr. Ramesh Juneja remains actively engaged, personally connecting with all of them over phone calls.